🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by TikTok fitness influencers and vendors on communication apps, according to new investigations.

Experimental Treatment Gaining Popularity Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are encouraged to contact these profiles privately for source information, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on messaging services, where communities with numerous of participants share comparison images, administration instructions and assertions of next-day British shipping. Vendors market the substance there before directing buyers to other platforms for transactions.

Understanding The Experimental Drug

This medication is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Medical Experts Express Concerns

However, doctors and pharmacists have warned that the distribution of what remains an unlicensed medication in the United Kingdom is a cause for concern and could lead to users injecting products of unknown origin.

Some experts said the demand for the experimental drug could be linked to the rising price of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Marketing the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach medicines, marketing, and customer regulations, potentially leading to penalties, legal action or imprisonment.

Service Response and Content Removal

Based on TikTok, the platform has taken down problematic content and banned related hashtags and query recommendations. The organization stated it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.

Digital Marketplace Activities

Research also found groups with up to nine thousand members marketing the experimental drug using Telegram's integrated search feature, which functions like a public directory. Typing “retatrutide” instantly brings up channels with thousands of members, filled with images of slimming results, positive testimonials and detailed instructions for mixing or administering at residence.

After minutes of joining one community, a seller posted WhatsApp details, where most purchases take place. The seller sent an instruction manual and promised delivery within two days. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about weight, health issues or past usage.

Item Details and Costs

Inside these groups, posts show black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at residence with purified liquid, or ready-to-use pens typically sold at £160 for 20 milligrams. When asked how much time a pen should last, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for Telegram stated it actively moderated dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering materials they can’t verify. Although the science behind this drug is sound, these online products may not include what they claim,” said a pharmacy expert, the head of pharmacy at Chemist4U.

A medical professional of an online medical service linked the increase in demand to current cost increases for approved slimming medications such as Mounjaro. “With prices rising, patients are turning to social media. But fake treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she said.

Her team has already seen individuals harmed by self-injection from unverified sources. “We understand the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Producer Position

A spokesperson from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been evaluated or approved by any government authority globally. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet approved … may subject patients to potentially significant medical dangers”.